- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04112550
Clinical Effectiveness of Pre-operative Methadone in Single Level Lateral Transpsoas Interbody Fusions
Clinical Effectiveness of Pre-operative Methadone in Single Level Lateral Transpsoas Interbody Fusions: A Randomized, Double-blinded, Controlled Trial
Spinal operations including lumbar fusions for degenerative disorders are becoming more prevalent as the population ages. Inadequate or excessive postoperative analgesia can result in medical comorbidities and prolonged hospital length of stay and patient dissatisfaction.
Existing literature has highlighted the preoperative administration of methadone as a promising adjuvant for post operative pain control. Methadone has the benefit of being long-acting and has more stable serum concentration and a single preoperative dose may have significant benefits post operatively.
Here the investigators propose a prospective parallel-group, randomized, double-blinded study to assess post operative analgesic requirements after preoperative administration of either methadone 15 mg or Oxycodone 10/325. Primary outcome will be total IV and PO narcotic consumption in the post operative course. Secondary outcomes examined will include time to mobility, need for specialist pain management consultation, early readmission (within 2 weeks) for inadequate pain control, and complications associated with administration.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Lumbar spinal fusions are becoming increasingly popular and prevalent in the treatment of a variety of spinal pathologies, but predominantly for degenerative disease which is most prevalent in the obese and or older population. These operations can result in relatively high post operative surgical pain and necessitate significant post operative opioid consumption which can precipitate co-morbid medical conditions such as respiratory depression and failure, pneumonia, gastrointestinal ileus, deep venous thrombosis, and pulmonary embolism. Additionally, these medical comorbidities also represent an increased burden on healthcare expenditure with increased length of hospital stay, inpatient testing and treatment, and need for additional follow up.
The investigators objective is to study the effect of a long term opioid analgesic, methadone, in a uniform population undergoing a single level minimally invasive lumbar fusion. The preoperative single dose administration of methadone has already been shown to be effective in improving post operative pain control in open multi-level spinal fusion patient populations and has become the standard of care in most surgical centers across the country. The long half-life of methadone results in improved steady state pharmacokinetics relative to other traditional opioids and is thought to improve pain control while decreasing consumption. In addition to Mu opioid receptor agonism, Methadone is thought to also have adjunctive analgesic and anti-tolerance effects due to CNS excitatory glutamatergic NMDA receptor antagonism. There are also reports of synergistic effects from serotonin and norepinephrine reuptake inhibition.
The investigators predict that a single preoperative oral methadone administration can result in improved postoperative analgesia with requirement of less IV and PO traditional narcotics within the first 2 weeks post operatively and also will not increase co-morbid risks relative to traditional shorter acting opioid analgesics that are presently given preoperatively.
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Saeed S Sadrameli, MD, MS
- Número de teléfono: 2817431385
- Correo electrónico: ssadrameli@houstonmethodist.org
Copia de seguridad de contactos de estudio
- Nombre: Marcus S Wong, MD
- Número de teléfono: 8324574452
- Correo electrónico: mswong@houstonmethodist.org
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age: 18 - 70
- Will undergo one level minimally invasive lumbar fusion surgery
- Primary symptoms are back and/or leg pain
Exclusion Criteria:
- Preoperative chronic renal insufficiency or failure (defined as a serum creatinine more than 2 mg/dl)
- Significant liver disease (cirrhosis or hepatic failure)
- American Society of Anesthesiologists (ASA) physical status IV or V
- Pulmonary disease necessitating home oxygen therapy
- Patients with acute bronchial asthma or hypercarbia
- Patient who has or is suspected of having a paralytic ileus
- Preoperative use of methadone or hydromorphone
- Known hypersensitivity to methadone
- Known hypersensitivity to oxycodone
- Recent history of opioid or alcohol abuse
- Inability to use a PCA device
- Inability to speak English
- Any patient judged by the anesthesia care team to potentially require prolonged postoperative intubation
- Participation in another clinical trial
- Inability of patient to provide study informed consent (including patients who are cognitively impaired)
- Presence of drug interaction between methadone/oxycodone and patient's regular or PRN medications
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: Methadone
This cohort will receive oral methadone 15mg po tablet pre-operatively
|
FDA approved medication to treat pain
|
Comparador activo: Oxycodone
This cohort will receive oxycodone/acetaminophen 10/325 po tablet pre-operatively
|
FDA approved medication to treat pain
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Post-operative in-hospital patient's narcotic requirement
Periodo de tiempo: Post-operative day 0 to 4
|
The total Morphine Milligram Equivalent (MME) for each post-operative day
|
Post-operative day 0 to 4
|
Improvement in low back pain between the two cohorts as assessed by Oswestry Disbility Index (ODI)
Periodo de tiempo: 14 days
|
Change in ODI (scale from 0 to 100) from pre-op to post-op (14 days post-op)
|
14 days
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Sean M Barber, MD, The Methodist Hospital Research Institute
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Anticipado)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades musculoesqueléticas
- Enfermedades de la columna
- Enfermedades óseas
- Espondilólisis
- Espondilosis
- Degeneración del disco intervertebral
- Espondilolistesis
- Efectos fisiológicos de las drogas
- Depresores del sistema nervioso central
- Agentes del sistema nervioso periférico
- Analgésicos
- Agentes del sistema sensorial
- Agentes antiinflamatorios no esteroideos
- Analgésicos no narcóticos
- Agentes antiinflamatorios
- Agentes antirreumáticos
- Antipiréticos
- Analgésicos Opiáceos
- Estupefacientes
- Agentes del sistema respiratorio
- Agentes antitusivos
- Paracetamol
- Oxicodona
- Metadona
- Combinación de medicamentos con acetaminofén e hidrocodona
Otros números de identificación del estudio
- Pro00022567
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .